Breast Cancer

Bevacizumab Efficacious for HER2-Negative Breast Cancer

For patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the addition of bevacizumab to neoadjuvant chemotherapy improves the pathological complete response (pCR), according to two studies published in the January 26 issue of the New England Journal of Medicine.

Next post in Breast Cancer